Most of the HNSCC clinical trials testing anti-CTLA-4 recruited patients who previously received ablative locoregional therapies since HNSCC is prone to regional lymphatic metastasis (D'Cruz et al., 2015; Chow, 2020; Mody et al., 2021). This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.